CCC
BIIB icon

Crescent Capital Consulting’s Biogen BIIB Stock Holding History

Crescent Capital Consulting’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$48K Buy
+200
New +$51.4K 0.01% 294

Other funds holding BIIB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Crescent Capital Consulting's BIIB Position: Q4 2021 in Review

Crescent Capital Consulting opened a new position in Biogen (BIIB) in Q4 2021: 200 shares worth $48K. The stake represents 0.01% of the portfolio and ranks #294 among its holdings.

1,009 funds tracked by Wall St. Rank hold BIIB as of Q4 2021.

  • Crescent Capital Consulting held 200 shares of Biogen worth $48K as of Q4 2021.
  • Biogen was a new Crescent Capital Consulting position in Q4 2021.
  • Biogen made up 0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #294 holding.
  • 1,009 funds tracked by Wall St. Rank held Biogen as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.